Finasteride and Proviron Interaction: Avoid | Peptide Database

Join others researching FGL — share findings, ask questions, and learn from real experiences FGL is a synthetic peptide derived from the second fibronectin type III module of neural cell adhesion molecule (NCAM). It mimics the interaction between NCAM and fibroblast growth factor receptor 1 (FGFR1), activating downstream signaling cascades that promote synaptic plasticity, neurogenesis, and neuroprotection. Research has primarily been conducted in animal models, where FGL has shown promise for cognitive enhancement, stroke recovery, and neurodegenerative disease models. FGL binds to and activates FGFR1, triggering receptor autophosphorylation and downstream signaling through the MAPK/ERK and PI3K/Akt pathways. This activation promotes long-term potentiation (LTP), enhances synaptic plasticity, stimulates neurogenesis in the hippocampus, and provides neuroprotective effects against excitotoxicity and oxidative stress.

Join others researching Dapoxetine — share findings, ask questions, and learn from real experiences Dapoxetine is the first and only selective serotonin reuptake inhibitor (SSRI) specifically developed and approved for the on-demand treatment of premature ejaculation (PE) in men aged 18-64. Unlike conventional SSRIs such as paroxetine or sertraline -- which are sometimes used off-label for PE but require daily dosing and weeks to reach therapeutic effect -- dapoxetine was engineered for rapid absorption and short elimination, making it suitable for as-needed use 1-3 hours before sexual activity. Originally developed by Eli Lilly and later licensed to Johnson & Johnson (ALZA Corporation), dapoxetine received its first regulatory approval in Sweden in 2009 under the brand name Priligy, and has since been approved in over 50 countries across Europe, Asia, Latin America, and the Middle East. It has not received FDA approval in the United States despite multiple submissions. Dapoxetine works by increasing serotonin activity at the postsynaptic cleft in the ejaculatory reflex pathway, raising the threshold for ejaculation and improving control over the timing of climax. Dapoxetine selectively inhibits the serotonin transporter (SERT) at presynaptic nerve terminals, blocking reuptake of serotonin (5-HT) from the synaptic cleft. This increases serotonin concentration at postsynaptic receptors in the neural circuits governing the ejaculatory reflex, particularly within the spinal ejaculation generator and supraspinal pathways. The ejaculatory process is modulated by serotonergic neurotransmission: higher serotonin levels at 5-HT1B and 5-HT2C receptors raise the ejaculatory threshold, delaying the emission and expulsion phases of ejaculation. Unlike traditional SSRIs that require 1-2 weeks of daily dosing to achieve steady-state serotonin levels, dapoxetine reaches peak plasma concentration within approximately 1-2 hours after oral administration and is rapidly eliminated (terminal half-life ~1.5 hours, with an initial half-life of ~1.4 hours). This pharmacokinetic profile enables acute, on-demand modulation of serotonergic tone without the sustained receptor desensitization seen with chronic SSRI use.